However, as previously highlighted, early trials using BRAF inhibitors as monotherapy in BRAF p.V600E-mutant metastatic mCRC yielded limited clinical benefit, primarily due to rapid feedback reactivation of EGFR and sustained MAPK signaling, mechanisms that are absent in melanoma. Here, BRAF is linked to melanoma.